Table 4—

Adverse experiences among women with and without type 2 diabetes, by treatment group

Diabetic women
Nondiabetic women
ALNPlaceboALNPlacebo
Experience leading to permanent discontinuation15.5 (23)12.8 (23)8.9 (276)10.1 (310)
Experience resulting in hospitalization10.8 (16)8.7 (13)4.9 (151)4.8 (147)
Upper gastrointestinal events
 Any53.4 (79)45.6 (68)43.2 (1,334)43.2 (1,327)
 Abdominal pain27.0 (40)*14.8 (22)13.1 (403)13.0 (400)
 Esophagitis2.7 (4)0.7 (1)0.7 (22)0.4 (13)
 Esophageal ulcer0.7 (1)0 (0)0.2 (6)0.2 (6)
 Other esophageal2.0 (3)2.0 (3)1.9 (57)1.6 (49)
 Acid regurgitation/reflux8.8 (13)6.7 (10)8.5 (262)8.3 (255)
  • Data are percent (n).

  • *

    * P < 0.05 for diabetic women in the ALN vs. placebo treatment arm.